Cookie preferences

Essential storage keeps iPulse AI reliable. Optional analytics and LinkedIn ad measurement stay off unless you accept. Privacy Policy

Skip to main content
Sana Biotechnology logo
SANA.NASDAQ
Sana Biotechnology
Health Care · Biotechnology

Biotechnology company developing engineered cells and gene therapies for oncology, diabetes, autoimmune, and genetic diseases.

HQ: United StatesListed: United States

SANA: Sana Biotechnology Stock Price, Analysis & Forecast: 1 Year and 5 Year Targets

Updated Deep analysis published 12 min read
Approved byRusslan Ramdowar, Editor-in-Chief

Sana Biotechnology: 1-Year and 5-Year Forecast Outlook and Rating

Sana Biotechnology (SANA) has an immediate Strong Buy & Keep consensus AI recommendation, based on 11 AI analysts.

  • The 1-year target is $2.02 for , with +27.04% expected return (+27.04% including net dividends) and a STRONG BUY rating.

  • The 5-year target is $2.65 for , with +66.67% expected return (+66.67% including net dividends) and a BUY rating.

Latest available market price: USD 1.59, as of 20 Nov 2026.

Dividend calculation details

Calculated net annual dividend yield: 0%. As of 2026-11-20.

Gross TTM: 0% · Two-year annualized gross: 0%.

Tax withholding assumption: 30% (US). One-off special payments are excluded.

Original published assumption: 0% per year.

Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.

Targets retain their original publication dates. Returns use the dated market close and the time remaining to each fixed target date. Current ratings also require fresh quotes and analysis, with more than 90 days remaining. Past targets have no forward return. Eligibility checked .

Sana Biotechnology Flagship Insight

The Science Advances, but Financing Determines Who Owns the Breakthrough

Sana Biotechnology’s scientific option value rests on immune-evasive islets and targeted in vivo cell engineering, but repeated financing limits value retained per share. High consensus favors genuine biological relevance; sharp divergence concerns dilution-adjusted valuation. Replicated SC451 efficacy, manufacturing consistency and funded runway determine durable repricing.

How were the Investment Thesis and Forecasts created?

11 AI advisors, guided by 9 analytical frameworks, contribute to the deep analysis by iPulse AI Engine.

  • Universal Investor (Polymath)
  • Sherlock Holmes (Whistleblower)
  • Michael Burry (Vulture)
  • Warren Buffett (Value Purist)
  • Superintelligence (Anthropologist)
  • Machiavelli (Insider)
  • Ray Dalio (Strategist)
  • Elon Musk (Visionary)
  • J.P. Morgan (Titan)

Ran across these frontier AI models

  • OpenAI GPT-6.1 Sol
  • Google Gemini 4 Hydrogen
  • Anthropic Claude Opus 5.5

Latest published deep-analysis batch. Audit published forecasts in full transparency

Sana Biotechnology: Investment Thesis Summary

Dotted terms link to the glossary; hover or focus for a preview. Browse technical terms

If you invest $10,000 in Sana Biotechnology at the latest market close (20 Nov 2026): $16,667 by Nov 2031 versus $14,502 for S&P 500 benchmark.

Returns use the same dated market close, fixed targets and remaining dividend period as the forecast table.

Five-year synthesized consensus forecast for Sana BiotechnologyThe diagram shows the synthesized consensus value path for Sana Biotechnology, forecast milestones, and a comparison with S&P 500 benchmark. excluding any dividend yield adjustment.$10,000$12,500$15,000$17,500$16,667 (+66.67%)$14,502 (+45.02%)Latest close2026-11-202027(1Y)2028(2Y)2029(3Y)2030(4Y)2031Fixed target
Sana Biotechnology · ConsensusS&P 500 benchmark
Figure: Five-year synthesized consensus value path for Sana Biotechnology compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

Sana’s equity is a claim on clinical progress after financing and contractual deductions, not simply on the size of the diabetes opportunity. Published donor-islet survival without immunosuppression supports immune-evasion biology, but does not establish SC451 insulin independence, therapeutic dosing or reproducible manufacturing. The base case assumes incremental clinical validation and continued external funding, with enterprise value advancing faster than existing shareholders’ retained interests. Valuation is therefore highly sensitive to issuance prices, development duration and net partnership proceeds. The strongest counterargument is reflexive upside: replicated efficacy could simultaneously increase pipeline value and reduce dilution. Available evidence establishes neither compelling underpricing nor an assured financing rescue.

Key insights

  • Clinical replication has two valuation channels: higher technical success probabilities and better funding terms, making evidence quality more important than headline patient counts.
  • Outsourcing reduces stranded infrastructure risk but moves investment into operating expenses, so low reported capex can conceal rising cash requirements per cohort.
  • Partnership economics must be assessed after contingent payments, royalties and surrendered rights; a smaller clean transaction may preserve more value than headline consideration.

Continue reading Sana Biotechnology analysis with Base subscription

See Base access
Protected research workspace

Sana Biotechnology: 5 Year Consensus Forecast

20 quarterly price targets, returns and rationale, with advisor range and benchmark

Forward returns are updated using the latest market close price of USD 1.59, as of 20 Nov 2026.

Dividend calculation details

Calculated net annual dividend yield: 0%. As of 2026-11-20.

Gross TTM: 0% · Two-year annualized gross: 0%.

Tax withholding assumption: 30% (US). One-off special payments are excluded.

Original published assumption: 0% per year.

Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.

The consensus target follows an expert-weighted price path synthesized from 11 AI advisor opinions. See Opinion weights and rationale for the exact allocation and reasoning.

Forecast methodology and reference values

Published targets are anchored on 13 Nov 2026 at USD 2.02. Original quarter-to-quarter target changes are retained. Forward returns use the remaining time to each fixed target date.

The pessimistic and optimistic advisor base cases are the lowest and highest published advisor base-case targets for each quarter. The advisor at either extreme can change between quarters. Benchmark values are in USD.

Scroll the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in USD, with price returns, cumulative returns including net dividends and rationale; separate individual advisor range, benchmark and applicable FX forecasts
QuarterConsensus target (USD)Forecast quarter-to-quarter price changeForward price returnForward return incl. net dividendsForecast rationalePessimistic Advisor Base Case (USD)Optimistic Advisor Base Case (USD)S&P 500 benchmark (USD)
$1.80-10.95%+13.21%+13.21%Financing urgency outweighs anticipated clinical entry as the disclosed runway shortens. Elevated capital costs amplify the discount on unproven programs, while existing human feasibility evidence supports residual option value rather than immediate funding security.$1.78$1.92$736
$1.69-6.17%+6.29%+6.29%The scenario remains dominated by ownership sold to extend operations before decisive clinical evidence. Initial dosing could improve confidence, but the higher-weighted paths assume enrollment progress cannot yet neutralize issuance discounts and uncertain funding duration.$1.52$2.04$724
$1.97+16.82%+23.90%+23.90%Assumed financing completion and initial SC451 or SG293 observations shift attention from immediate survival toward biological translation. The recovery depends on interpretable function and operational continuity, not established insulin independence, durable responses or a guaranteed partnership.$1.56$2.36$722
$2.02+2.46%+27.04%+27.04%Additional patient observations support a measured recovery in pipeline credibility, but the reports disagree on whether financing lands before or after encouraging data. Dilution and rising trial commitments restrain the value accruing to each existing share.$1.64$2.26$724
$1.99-1.49%+25.16%+25.16%Attention shifts from early signals to persistence, reproducibility and the next funding requirement. Some scenarios allow fresh capital or favorable follow-up to help, but continued cash consumption keeps the balance cautious after the initial rebound.$1.58$2.45$735
$2.11+5.79%+32.70%+32.70%Broader follow-up and additional evaluable patients improve the modeled case for persistent function. Funding needs remain disputed, yet the more heavily weighted scenarios give incremental clinical replication greater valuation importance than immediate capital-supply pressure this period.$1.47$2.47$752
$2.17+3.08%+36.48%+36.48%Cohort expansion and more consistent supply support modest development-value gains, while manufacturing comparability work and renewed financing plans limit enthusiasm. The balance favors operational progress without assuming a transformative licensing agreement or definitive clinical validation.$1.55$2.62$754
$2.14-1.60%+34.59%+34.59%Another financing installment can absorb the benefit of improving durability and process execution. The competing positive case emphasizes longer follow-up and partner interest, but retained ownership remains the binding distinction between enterprise progress and per-share value.$1.46$2.78$780
$2.19+2.78%+37.74%+37.74%Replenished funding and longer observation allow investors to revisit dose-response and graft persistence rather than merely detectable activity. Competitive updates and expanding trial costs remain material offsets, leaving the modeled improvement dependent on clinically meaningful consistency.$1.39$2.65$802
$2.28+3.68%+43.40%+43.40%Clearer study design and accumulating cohort evidence improve the financeability of subsequent development. Some paths instead place another equity raise here, so the favorable balance reflects reduced clinical uncertainty rather than assuming unencumbered strategic cash inflows.$1.44$2.83$819
$2.25-1.12%+41.51%+41.51%Manufacturing comparability, trial expansion and another funding installment again test shareholder participation. Favorable clinical and enrollment scenarios provide support, but the weighted balance discounts the cash required before broader programs can deliver a more decisive efficacy assessment.$1.34$2.97$821
$2.30+2.41%+44.65%+44.65%Assumed durability observations and clearer subsequent development plans rebuild pipeline credibility after funding pressure. Variable responses and competitive treatment standards prevent a full product valuation, while recurring losses keep any improvement dependent on evidence rather than reported accounting earnings.$1.26$2.86$842
$2.34+1.65%+47.17%+47.17%Longer clinical follow-up and more measurable later-stage plans offer incremental support, despite divergent views on rival progress and financing timing. The scenario values reduced execution uncertainty without assuming commercial sales, accelerated approval or a transaction rescue.$1.32$3.02$863
$2.33-0.50%+46.54%+46.54%Larger-study funding needs broadly offset assumed improvements in manufacturing consistency and patient handling. Some scenarios anticipate limited licensing support, but the balance remains restrained because operational continuity still requires capital before meaningful recurring revenue becomes credible.$1.22$3.12$871
$2.41+3.28%+51.57%+51.57%Post-financing execution, consistent product release and longitudinal graft observations improve the modeled development case. Competitive readouts and scale-up costs still constrain the premium, so appreciation reflects narrower uncertainty rather than an established manufacturing or commercial moat.$1.17$3.13$874
$2.47+2.70%+55.35%+55.35%Extended follow-up and clearer late-stage requirements support further clinical-value recognition, partly offset by renewed financing concerns. More optimistic filing scenarios receive limited weight; the central case needs credible progression, not an assumed regulatory submission on schedule.$1.20$3.26$896
$2.38-3.69%+49.69%+49.69%Monitoring, manufacturing validation and continuing development commitments expose the funding still required before commercialization. A minority case gains from completed financing, but most weighted scenarios again discount ownership transferred and contractual claims against distant cash generation.$1.15$3.14$912
$2.54+6.69%+59.75%+59.75%Continued follow-up, recruitment execution and reliable product supply strengthen the case for a financeable later-stage program. Potential collaborations add support, yet the improvement does not require an approval decision or confirm that future partnership proceeds remain unencumbered.$1.10$3.32$924
$2.57+1.02%+61.64%+61.64%Cross-site reproducibility and operational consistency add modest support, while payer economics, rival programs and commercial-scale validation costs limit the gain. The balance remains sensitive to whether better evidence improves retained shareholder economics before further funding is needed.$1.14$3.54$939
$2.65+3.22%+66.67%+66.67%The horizon closes with stronger clinical options but a substantially expanded ownership base. Credible next-stage plans support value, while unresolved approval, funding and reimbursement work prevent scientific progress from being mistaken for a self-financing commercial franchise.$1.11$3.40$965
Show remaining 18 quartersCollapse to first 2 quarters

All 20 quarters are displayed in the table above.

Sana Biotechnology Stock Analysis & Scenarios Deep Dive

Sana Biotechnology: Alpha Gap & Repricing Catalysts

Market Narrative

What does the market currently expect? Supplied analyst summaries remain optimistic about diabetes cell replacement, while November 2026 price commentary emphasizes lows and imminent dilution. These are opposing narratives, not verified market-wide positioning. Pricing plausibly reflects financing anxiety, but does not reveal a unique clinical-success probability. Some descriptions of speculative enthusiasm lack external support, and cited analyst estimates are not a fresh consensus survey.

Alpha Gap

What is the biggest difference between market expectations and our AI forecasts? The reports establish no compelling directional gap. The strongest analytical edge is the link between clinical replication and the ownership waterfall: valuable science can coexist with mediocre per-share economics when issuance, royalties and contingent payments absorb development gains. That challenges optimistic analyst extrapolations, without proving the traded shares are overpriced. Conversely, convincing multi-patient efficacy could improve both asset value and financing terms. Market-wide expectations and fair value remain insufficiently evidenced.

Repricing Catalyst

What could make the market recognize and close that gap? Replicated SC451 function paired with funding beyond the next meaningful readout is the decisive trigger, because neither biology nor liquidity alone resolves the ownership problem. H1 2027 financing and dosing disclosures would establish continuity; conditional 2027–2028 cohort durability would test translation. Through 2029–2031, manufacturing consistency and funded later-stage plans could sustain recognition. Favorable repricing requires clinical de-risking to exceed dilution and contractual leakage; this remains disputed, not assured.

Sana Biotechnology: Sentiment and Timing

What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?

Greed and Fear Sentiment
Fear
Volatility Regime
High Erratic
Convergence Cycle Position
Mixed

Fear and erratic volatility are broadly consistent, but cycle interpretations split between continuing reversal and tentative stabilization. Financing completion could remove immediate survival pressure without establishing attractive retained economics, making sustained clinical confirmation more important than a temporary relief rally.

Macro Regime Fit

Does the current market environment support the thesis? The supplied regime is a headwind: elevated yields discount distant therapeutic cash flows and worsen equity-financing terms. For a company without product sales, capital availability matters more than current demand sensitivity. Disinflation and reopened biotechnology issuance could help, but neither substitutes for clinical evidence or removes manufacturing and funding obligations.

Advisor Disagreement

What do our AI Advisors disagree about most? The central economic disagreement is whether clinical progress improves financing terms fast enough to preserve ownership. Some scenarios allow early data to secure strategic funding and later-stage progress; others assume years of issuance with little retained equity benefit. The defensible bullish case requires both replication and better financing prices, not biomarkers alone. Apparent capitalization disagreements partly reflect outstanding versus diluted weighted-average shares, while inconsistent research-spending mappings exaggerate expense changes. Cohort-level function and net cash retained after financing would resolve more than optimistic approval calendars.

Thesis Change

What changed in the thesis since the previous forecast? The core science-versus-financing tension persists, but stronger accounting and contractual evidence materially weakens the prior claim of clear underpricing today. -- The prior thesis treated donor-islet evidence as broad platform validation; current reports distinguish immune-evasion feasibility from unproven SC451 therapeutic efficacy and manufacturing replication. -- The September 2026 reporting period brings lower liquidity and explicit going-concern uncertainty; amended contingent obligations also absorb qualifying partnership proceeds, weakening the prior assumption that licensing cleanly solves dilution.

Sana Biotechnology: Critical Influencing Factors

Near-certain positive forcesTop Drivers & Tailwinds

Near-certain forces that support the investment thesis. These forces are treated as part of the base case (at least 75% probability of occurrence, as generation guidance). Impact columns are specific to this asset class.

Scroll to view all columns

Top Drivers & Tailwinds with asset-specific estimated impacts and thesis rationale
Driver / TailwindCategoryEst. stock-price impactEst. earnings impactWhy it matters
Immune evasion retains option valueInnovation And Product+50%+0.0%Human donor-islet persistence without immunosuppression gives the platform a credible biological starting point rather than a purely preclinical story. That evidence should retain relevance across the horizon and support risk-adjusted pipeline value. It does not establish SC451 insulin independence or manufacturability, so the benefit is principally valuation support rather than near-term earnings.
In vivo delivery preserves alternativesInnovation And Product+30%+0.0%Targeted in vivo CAR T engineering preserves a second route to value beyond diabetes. Surrogate primate data support delivery and B-cell depletion, while avoiding individualized cell production could improve eventual treatment economics. The architecture should remain strategically relevant, but human efficacy, specificity and tolerability are unproven; continued relevance is not a funded partnership.
Fewer factories, more informative experimentsOperational Efficiency+20%+15%Portfolio concentration and the halt to internal manufacturing expansion make each financing dollar support a narrower set of informative experiments. This leaner structure should persist because liquidity remains scarce. Outsourcing reduces fixed commitments and normalized losses, but trial expansion can still lift total spending; lower capex is not equivalent to low cash requirements.
Clinical infrastructure reduces delivery frictionCompetitive Positioning+20%+5.0%Mayo Clinic’s collaboration addresses a practical bottleneck: consistent handling, delivery and monitoring of living cells across treatment sites. Its completed investment and clinical infrastructure strengthen execution credibility over the development cycle. The operational benefit survives scrutiny, but an expired additional investment option means the alliance cannot be treated as an open-ended financing backstop.

Near-certain negative forcesTop Frictions & Headwinds

Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (at least 75% probability of occurrence, as generation guidance). Impact columns are specific to this asset class.

Scroll to view all columns

Top Frictions & Headwinds with asset-specific estimated impacts and thesis rationale
Friction / HeadwindCategoryEst. stock-price impactEst. earnings impactWhy it matters
Financing transfers tomorrow’s ownershipCapital Allocation-45%-0.0%Repeated equity funding is likely to transfer a substantial portion of future enterprise appreciation to new capital before commercialization. The disclosed runway and going-concern uncertainty make financing a core operating requirement, not optional balance-sheet management. Clinical progress can therefore raise total company value while existing shares capture less; dilution changes ownership, not company-level earnings.
Clinical translation keeps consuming cashOperational Efficiency-30%-20%Manufacturing, therapeutic-dose testing and long-term safety follow-up remain unavoidable cash demands even if early biomarkers are encouraging. SC451 must translate donor-islet biology into a reproducible stem-cell product, while both lead programs require clinical supply and quality systems. These obligations should persist across the horizon, widening development losses and delaying monetization without requiring outright clinical failure.
Better-funded rivals raise the hurdleCompetitive Positioning-20%-10%Better-funded rivals raise the clinical and commercial standard Sana must meet, limiting the value investors can capitalize today. Vertex’s islet programs and competing engineered-cell therapies bring manufacturing resources and development endurance. Blood-type compatibility is not equivalent to immune evasion, but competition still constrains potential market share, licensing leverage and eventual pricing.
Success carries contractual tollsCapital Allocation-12%-8.0%Contractual participation means platform success does not flow unencumbered to common shareholders. Cobalt-related contingent payments and business-development triggers, together with royalty-bearing arrangements, can reduce retained licensing proceeds and future product economics. These claims remain relevant through development and strategic transactions, although payment timing is conditional and they are not all immediately payable funded debt.

Sana Biotechnology: What Could Break or Accelerate the Thesis

Event Risk Score: Very High 97/100Asset-level relative pressure from clustered consensus frictions and tail risks. This is not the probability or risk score of an individual force.

Plausible downside scenariosTail Risks

Tail yet plausible downside scenarios selected for their highest potential impact.

Scroll to view all columns

Tail risks with plausibility, asset-specific potential impact and scenario rationale
Tail scenarioChance of OccurringStock Price ImpactWhy plausible / what changes
SC451 fails the translation test35%-75%A decisive SC451 efficacy failure, clinically important rejection or serious treatment-related safety finding during 2027–2029 could halt development and undermine the principal translation of the immune-evasion platform. Partnering leverage would deteriorate as spending continues, compounding financing stress. This is a combined thesis-breaking event, not the probability of any specific toxicity; existing human feasibility evidence offers support but cannot exclude failure.
Funding closes before clinical conviction30%-60%A failed funding round or deeply discounted rescue before the projected mid-2027 runway endpoint could force program suspension, restrictive asset sales or a punitive recapitalization. Delayed or inconclusive data would weaken negotiating power precisely when cash becomes scarce. Prior market access and strategic relationships provide alternatives, keeping this below a base-case probability; unlike routine dilution, the event transfers value under duress.

Plausible upside scenariosTail Opportunities

Tail yet plausible upside scenarios selected for their highest potential impact.

Scroll to view all columns

Tail opportunities with plausibility, asset-specific potential impact and scenario rationale
Tail scenarioChance of OccurringStock Price ImpactWhy plausible / what changes
SC451 crosses the independence threshold30%+220%A disclosed SC451 cohort demonstrating durable insulin independence without immunosuppression during 2027–2029 would bridge the critical gap between donor-islet feasibility and a scalable therapeutic product. Reassuring safety, therapeutic dosing and consistent manufacturing would raise approval probabilities while improving funding terms. The probability remains limited because existing single-patient UP421 evidence establishes neither insulin independence nor reproducible stem-cell translation.
A partner funds clinical expansion25%+120%A substantial pharmaceutical licensing agreement after convincing SC451 or SG293 human data, plausibly during 2027–2030, could shift later-stage development costs to a partner and reduce discounted equity issuance. The trigger is reproducible function with acceptable safety, not sector deal headlines alone. Limited clinical maturity, alternative assets and contractual participation keep the event speculative; headline proceeds would exceed cash retained.

Company Financial AnalysisSana Biotechnology: Earnings and Financials Analysis by AI

Financial figures available as of Nov 16, 2026. Only filings and source records available by this analysis date are included. View latest Sana Biotechnology financials here.

Earnings and financials

Sana’s November 5 issuer release shows that the Q3 2026 profit of $20.4 million did not come from selling therapies. A $63.4 million noncash gain from revaluing contingent consideration and success-payment obligations outweighed continuing research and administrative losses. The headline therefore describes liability accounting, not a commercial turnaround. The supplied trailing-twelve-month results still show no recurring revenue and substantial free-cash outflows. Portfolio cuts lowered the cost base, but cash continues to finance experiments rather than replenish itself. Better clinical results could increase business value before improving earnings; whether shareholders benefit depends on how much ownership must be sold along the way.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal yearRevenueNet incomeFree cash flow
2025USD 0USD -244.2MUSD -144.8M
2024USD 0USD -266.8MUSD -256.6M
2023USD 0USD -283.3MUSD -273.6M
2022USD 0USD -266.4MUSD -310.9M
2021USD 0USD -344.2MUSD -280.9M

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal yearP/EEarnings basisCurrency basisTicker / reporting
2025--TTMLoss-makingUSD / USD
2024--TTMLoss-makingUSD / USD
2023--TTMLoss-makingUSD / USD
2022--AnnualLoss-makingUSD / USD
2021--AnnualLoss-makingUSD / USD

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

Margins are undefined, not merely poor, because Sana has no recurring product sales. The supplied trailing-twelve-month operating loss of roughly $146 million is more informative than a profit margin. Earlier loss narrowing followed suspended programs, lower overhead and reduced infrastructure commitments, rather than stronger pricing or higher sales. The issuer’s quarterly research figures also conflict with some supplied mappings, so an abrupt cost surge is not a reliable conclusion. Spending can still rise as trials broaden, even if each experiment becomes more efficient. Liability revaluations can reverse apparent net profitability without changing operations. The factor earnings estimates are directional loss sensitivities, not conventional growth rates or additive forecasts.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal yearOperating incomeOperating marginNet margin
2025USD -191M----
2024USD -272.7M----
2023USD -293.1M----
2022USD -272.6M----
2021USD -356.9M----

Balance sheet and leverage

Sana’s September 30, 2026 Form 10-Q reports $121.7 million in cash and marketable securities and substantial doubt about continued operations without new funding. Management’s projected runway into mid-2027 is far shorter than the likely development cycle. The immediate weakness is cash consumption, not conventional funded borrowing. Reported debt ratios do not capture the full problem. Operating leases remain payable despite reduced use of facilities, while Cobalt-linked payments and Mayo royalties can claim part of future success. These obligations are not all immediately payable debt, and their value should not simply be subtracted from cash. Nevertheless, they limit strategic flexibility and the proceeds common shareholders ultimately retain.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal yearTotal debtCash + short-term investmentsReported net cash / (debt)Debt less (cash + short-term investments), calculatedCurrent ratio
2025USD 78.9MUSD 138.4MUSD 7M net debtUSD -59.5M1.89x
2024USD 94.2MUSD 152.5MUSD 33.4M net cashUSD -58.3M3.54x
2023USD 104.1MUSD 205.2MUSD 29.4M net cashUSD -101.1M3.31x
2022USD 108.3MUSD 424MUSD 68.5M net cashUSD -315.7M3.99x
2021USD 110.9MUSD 551MUSD 142.1M net cashUSD -440.1M5.62x

Reported net debt retains the source definition, which can deduct cash alone. Cash plus short-term investments is broader liquidity; the separately calculated column subtracts that full amount from total debt for the same fiscal period and currency. Reported net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

Sana’s November 5 disclosures report just $2.7 million of property purchases in the first nine months of 2026, but low equipment spending understates the investment burden. The supplied fiscal 2025 research total was $132 million, and outsourced manufacturing and process development are generally expensed rather than recorded as new factories. Stopping the Bothell build-out and narrowing the pipeline conserve cash and reduce the risk of idle assets. They do not make living-cell development inexpensive: external manufacturers still charge for batches, testing and process transfers. The trade-off is fewer fixed commitments but greater vendor dependency. Issuer figures take precedence over inconsistent quarterly spending mappings, so a dramatic spending rebound is not established.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal yearCapital expenditureR&D spend
2025USD 938KUSD 132M
2024USD 33.4MUSD 208.7M
2023USD 20MUSD 219.8M
2022USD 20.9MUSD 201M
2021USD 29.9MUSD 306.5M

Behind the synthesisSana Biotechnology: How Each Individual AI Forecaster Opinion Shapes the Global Consensus

11 opinions · 100/100 allocated

This publication’s recorded synthesis allocated voting influence across 11 advisor opinions. The weights and rationales below are retained from that synthesis.

The most defensible common pattern is biological feasibility constrained by financing duration. Human graft observations and filed liquidity disclosures address different causal legs; repeated citations to the same issuer releases do not add independent confirmation. The highest weights go to analyses distinguishing donor-islet evidence from SC451 therapeutic validation, correcting share-count and spending definitions, and modeling contractual deductions alongside dilution. The strongest bearish case survives: necessary fundraising can overwhelm per-share gains even when programs remain viable. However, book-value anchors do not establish liquidation protection or demonstrate overpricing, and assuming no monetizable progress is too restrictive. Optimistic regulatory shortcuts, automatic institutional backstops and precise approval calendars receive less weight. The unresolved question is whether replicated clinical function improves financing terms quickly enough; unsupported capital-drain narratives and inconsistent expense mappings do not resolve it.

Individual targets retain their original dates. Returns and ratings use the same latest available market close and dividend assumptions as the Consensus.

All 11 opinions
Universal Investor in an AI-generated research persona portrait

Universal Investor AI

Consensus weight Allocation: 22.0/100. Weight Allocation Rationale: Highest weight reflects traceable primary disclosures, explicit corrections to share-count and research-spending definitions, and a coherent financing-and-contractual waterfall. It separates existing human feasibility evidence from therapeutic validation without requiring approval within the horizon. Funding amounts, terminal ownership and clinical progression nevertheless remain scenario assumptions rather than independently established outcomes.

The 1-year target is $2.15 for , with +35.03% expected return and a STRONG BUY rating. The 5-year target is $3.11 for , with +95.59% expected return and a STRONG BUY rating.

J.P. Morgan in an AI-generated research persona portrait

J.P. Morgan AI

Consensus weight Allocation: 15.0/100. Weight Allocation Rationale: Primary filings and product-specific manufacturing guidance support a coherent distinction between scientific relevance and a reproducible medicine. The path does not require approval or acquisition, and contractual claims are treated separately from funded debt. Substantial funding assumptions remain uncertain, while supporting sources overlap with other reports rather than providing independent replication.

The 1-year target is $1.95 for , with +22.53% expected return and a STRONG BUY rating. The 5-year target is $2.70 for , with +69.83% expected return and a BUY rating.

Superintelligence in an AI-generated research persona portrait

Superintelligence AI

Consensus weight Allocation: 13.0/100. Weight Allocation Rationale: Strong weight reflects careful separation of human feasibility, clinical replication and ownership retained after financing. The report explicitly limits claims about market expectations and recognizes contractual deductions. Its primary evidence overlaps with other submissions, and peripheral technology classifications add little; modeled funding and terminal share counts remain material uncertainties.

The 1-year target is $2.04 for , with +28.23% expected return and a STRONG BUY rating. The 5-year target is $2.88 for , with +81.04% expected return and a BUY rating.

Warren Buffett in an AI-generated research persona portrait

Warren Buffett AI

Consensus weight Allocation: 11.0/100. Weight Allocation Rationale: The bearish ownership argument survives scrutiny because filed liquidity, going-concern uncertainty and recurring development costs support repeated financing. Its distinction between funded debt and other obligations is valuable. Weight is limited by book-value anchoring, optimistic assumptions about predictable financing damage and insufficient allowance for clinical evidence improving issuance terms.

The 1-year target is $1.83 for , with +14.83% expected return and a STRONG BUY rating. The 5-year target is $1.42 for , with -10.84% expected return and a PARTIAL SELL rating.

Elon Musk in an AI-generated research persona portrait

Elon Musk AI

Consensus weight Allocation: 10.0/100. Weight Allocation Rationale: Direct clinical-publication and filing receipts support the distinction between meaningful biology and unproven commercial translation. The ownership analysis correctly separates dilution from company earnings and recognizes contractual leakage. Weight is moderated by speculative addressable-market assumptions and large valuation sensitivities; its essential clinical and financing evidence substantially overlaps with other reports.

The 1-year target is $2.09 for , with +31.24% expected return and a STRONG BUY rating. The 5-year target is $3.40 for , with +114.04% expected return and a STRONG BUY rating.

Michael Burry in an AI-generated research persona portrait

Michael Burry AI

Consensus weight Allocation: 8.0/100. Weight Allocation Rationale: The analysis correctly connects manufacturing outsourcing, continuing lease commitments and dilution to retained shareholder value. Its downside case is economically plausible rather than merely contrarian. Lower weight reflects an insufficiently substantiated liquidation-cash estimate, compressed runway arithmetic and speculative legal or geopolitical contributions that do not independently establish the projected path.

The 1-year target is $1.75 for , with +10.20% expected return and a BUY rating. The 5-year target is $1.62 for , with +1.87% expected return and a PARTIAL SELL rating.

Machiavelli in an AI-generated research persona portrait

Niccolo Machiavelli AI

Consensus weight Allocation: 6.0/100. Weight Allocation Rationale: The accounting reconciliation, contingent-payment analysis and financing-before-data sequence are useful and economically coherent. However, institutional ownership does not guarantee a capital backstop, and favorable regulatory generalizations do not establish product-specific acceleration. Repeated issuer and syndicated sources provide less independent corroboration than their number suggests.

The 1-year target is $2.27 for , with +42.75% expected return and a STRONG BUY rating. The 5-year target is $3.38 for , with +112.78% expected return and a STRONG BUY rating.

Universal Investor in an AI-generated research persona portrait

Universal Investor AI

Consensus weight Allocation: 5.0/100. Weight Allocation Rationale: The financing-before-readout sequence and distinction between accounting gains and operating economics are persuasive. However, modeled cumulative funding and share issuance appear modest relative to the stated multiyear burn, without a sufficiently explicit funding bridge. Secondary-source repetition and unsupported competition-for-capital claims further limit confidence in the complete path.

The 1-year target is $1.91 for , with +19.93% expected return and a STRONG BUY rating. The 5-year target is $2.06 for , with +29.78% expected return and a NEUTRAL rating.

Sherlock Holmes in an AI-generated research persona portrait

Sherlock Holmes AI

Consensus weight Allocation: 4.0/100. Weight Allocation Rationale: The unexercised follow-on investment option and accounting-profit reconciliation usefully qualify strategic-backing narratives. Nevertheless, lease measurements are not consistently distinguished, peer transactions do not establish a valuation floor, and the later approval calendar is unusually specific. Those limitations reduce numerical weight while preserving the supported financing and contractual insights.

The 1-year target is $2.00 for , with +25.59% expected return and a STRONG BUY rating. The 5-year target is $2.86 for , with +79.86% expected return and a BUY rating.

Warren Buffett in an AI-generated research persona portrait

Warren Buffett AI

Consensus weight Allocation: 3.0/100. Weight Allocation Rationale: Low weight reflects absent source receipts, book-value anchoring and capitalization based on a potentially mismatched share count. The dilution mechanism remains credible, but the declining path assumes little monetizable clinical progress and applies established-business moat requirements too rigidly to a development-stage company.

The 1-year target is $1.65 for , with +3.57% expected return and a NEUTRAL rating. The 5-year target is $1.11 for , with -30.28% expected return and a SELL ALL rating.

Ray Dalio in an AI-generated research persona portrait

Ray Dalio AI

Consensus weight Allocation: 3.0/100. Weight Allocation Rationale: The macro-to-financing transmission is sound, and the scenario appropriately pairs clinical evidence with capital availability. Lower weight reflects reliance on an additional investment option contradicted by supplied filing-based accounts, precise later regulatory milestones and unverified transaction comparisons. Its repeated macro premises do not constitute independent evidence.

The 1-year target is $2.11 for , with +32.58% expected return and a STRONG BUY rating. The 5-year target is $3.01 for , with +89.04% expected return and a STRONG BUY rating.

References & Context

Research Provenance

Analysis generated by iPulse AI Engine v9 using recorded market data, operating under the editorial standards and supervision of Russlan Ramdowar, Editor-in-Chief.

External references below are sources recorded by the researcher agents for this Sana Biotechnology forecast batch.

Primary analysis inputs

  • iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
  • iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
  • Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
  • Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
  • Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Sources retained from AI Researcher searches

Asset-specific · Researcher web

40 available sources from this batch (96 recorded). The first 15 are shown below; expand to read the rest.

Some model providers retained only the consulted domain, not an exact article URL. Those domains are shown as evidence without inventing a link.

  1. sec.gov sec.gov
  2. 10-Q sec.gov
  3. FDA Provides Clarity to Support Cell and Gene Therapy Development and Quality | FDA fda.gov
  4. Long Term Follow-up After Administration of Human Gene Therapy Products | FDA fda.gov
  5. Human Gene Therapy Products Incorporating Human Genome Editing; Guidance for Industry hhs.gov
  6. nih.gov nih.gov
  7. 10-Q sec.gov
  8. 8-K sec.gov
  9. Sana Biotechnology, Inc. - Form 8-K - FY2026 sec.gov
  10. www.sec.gov sec.gov
  11. www.sec.gov sec.gov
  12. sana.com sana.com
  13. tradingview.com tradingview.com
  14. stocktitan.net stocktitan.net
  15. perplexity.ai perplexity.ai
Show 25 more sources
  1. investing.com investing.com
  2. tipranks.com tipranks.com
  3. vrtx.com vrtx.com
  4. biospace.com biospace.com
  5. gcs-web.com gcs-web.com
  6. globenewswire.com globenewswire.com
  7. Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates | Sana Biotechnology, Inc ir.sana.com
  8. koalagains.com koalagains.com
  9. longbridge.com longbridge.com
  10. morningstar.com morningstar.com
  11. noah.bio noah.bio
  12. rallies.ai rallies.ai
  13. seekingalpha.com seekingalpha.com
  14. firstwordpharma.com firstwordpharma.com
  15. Vertex Pharmaceuticals | Vertex Reports Third Quarter 2026 Financial Results investors.vrtx.com
  16. Form 10-Q for Sana Biotechnology INC filed 11/05/2026 ir.sana.com
  17. Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes | Sana Biotechnology, Inc ir.sana.com
  18. Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates | Sana Biotechnology, Inc ir.sana.com
  19. stockanalysis.com stockanalysis.com
  20. alliancerm.org alliancerm.org
  21. allsci.com allsci.com
  22. beyondtype1.org beyondtype1.org
  23. biocentury.com biocentury.com
  24. bioradar.io bioradar.io
  25. Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates - BioSpace biospace.com

56 additional sources are recorded in this batch; their citation details are not available in this publication.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

03

Global context snapshot

2026 Year-to-Date Global Market and World-Events Context Through November 14

Download Archived Snapshot

Coverage 2026-01-01 to 2026-11-14 · Knowledge cutoff 2026-11-14

January 1-November 14, 2026: persistent inflation, partial oil supply recovery, US midterms and trade, AI financing, and uneven growth.

Archived context covering 2026-01-01 to 2026-11-14. Its recorded scope includes monetary policy and rates; geopolitics energy and shipping; trade and industrial policy. Selected highlights reflect the analysis cutoff, not current world conditions.

Show moreShow less
File size
96K bytes
Words
14.2K words
Characters
96K characters
Est. tokens (characters ÷ 4)
24K tokens

Fed held at 3.75%-4.00%; Democrats won the next Congress, Nvidia changed leadership and Anthropic filed preliminary IPO terms. Markets through November 13.

Selected highlights from the archived 2026 Year-to-Date Global Market and World-Events Context Through November 14 snapshot
Selected highlights from this archived snapshotDateStatus
Renewed monetary tightening amid persistent inflation2026-01-30ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption2026-02-28ONGOING
US tariff reset, trade truce and incoming divided government2026-02-20ACTIVE POLICY REGIME

Representative Sources of the Context File

And more sources from the retained context package.

02

Fundamental Context Passed as Input to the Models

Time range: Annual fiscal periods: 2018-12-31–2025-12-31, 8 periods; Quarterly fiscal periods: 2023-12-31–2026-09-30, 12 periods.

Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).

Show moreShow less

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

10 fields

cash · commonStockSharesOutstanding · netDebt · shortLongTermDebtTotal · +6 more fields

Cash flow

4 fields

capitalExpenditures · freeCashFlow · salePurchaseOfStock · totalCashFromOperatingActivities

End of the paywalled preview

The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

  • Individual AI Advisor reports

    • Investment theses
    • Bull and bear scenarios and alpha signals
    • Drivers, headwinds, risks and opportunities
    • Quarterly forecast rationale
    • Advisor research references and configuration
  • Additional datasets and interactive tools

    • Interactive forecast comparisons
    • Available detailed financial statements
    • Market history and corporate-action adjustments
    • Eligible historical publication workspaces

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.

Sana Biotechnology: forecast questions

What is Sana Biotechnology (SANA)'s 1-year price forecast?

Sana Biotechnology's 1-year target is $2.02 for Nov 2027. The current AI rating is STRONG BUY. The expected return from the recorded close is +27.04%, or +27.04% modeled return including net dividends. Latest available market price: USD 1.59, as of 20 Nov 2026. The target date is fixed at publication.

What is Sana Biotechnology (SANA)'s 5-year price forecast?

Sana Biotechnology's 5-year target is $2.65 for Nov 2031. The current AI rating is BUY. The expected return from the recorded close is +66.67%, or +66.67% modeled return including net dividends. Latest available market price: USD 1.59, as of 20 Nov 2026. The target date is fixed at publication.

How can I compare the AI opinions and audit past Sana Biotechnology forecasts?

11 AI analysts contribute to this publication. AI Opinions shows individual advisor forecasts and reasoning. Forecast History lists the available batches with their original publication dates.

How does an AI-generated forecast for Sana Biotechnology differ from Wall Street analyst consensus?

Wall Street consensus aggregates estimates from human analysts. For listed companies, these typically include brokerage price targets, earnings forecasts and ratings. iPulse AI's forecast for Sana Biotechnology is a separate AI consensus generated through its own research workflow. Different inputs, forecast dates, assumptions and weighting can therefore produce different targets.

We believe the era of investment research conducted only by human analysts is drawing to a close. Frontier models increasingly match or exceed expert work on selected professional benchmarks, including evaluations covering financial analysis. Research on multi-model synthesis also shows that combining model responses can improve on a single model's output in the tasks studied.

iPulse AI generates transparent investment research and market forecasts using a swarm of AI configurations, analytical frameworks and frontier models. The workflow applies multiple verification, challenge and synthesis layers, with selective editorial review under Russlan Ramdowar, Editor-in-Chief. Published assumptions, disagreements and past forecasts remain available so readers can inspect the reasoning and audit outcomes.

For a research cycle covering 426 assets with 14 perspectives per asset, our internal workload model estimates approximately 114,000 hours of traditional analyst work. It assumes 16 hours per individual research report, 28 hours per consensus for synthesis and validation, plus shared data preparation. Parallel AI execution allows a deep-analysis cycle across hundreds of assets to complete in up to one day. The human-hours figure is an illustrative workload estimate, rather than measured time savings. Our research methodology explains the automated workflow.

If iPulse AI produces thousands of investment reports - work estimated to require over 100,000 traditional analyst hours - isn't that just "AI slop" at scale?

No. iPulse AI produces AI-generated research at scale, but the purpose is depth of analysis, comparison, and accountability. The number of reports is a consequence of the research process; it is not the goal.

iPulse AI does not produce thin copies of existing websites, articles, or investment reports. We use frontier models as an Analytical Intelligence layer. Our Financial Experts select, validate, curate, and supply the input data, including proprietary inputs, so the models work from a prepared evidence base.

In Researcher mode, models can also search the web to check current information, test assumptions, and investigate evidence that may be missing from the supplied data. This can include lobbying expenditure, management developments, regulatory decisions, or other facts relevant to a particular investment thesis. Thinker mode focuses on deep reasoning over the supplied data and context.

Our process goes much further than asking ChatGPT to evaluate a stock. Our team designs structured investment frameworks inspired by the approaches of influential investors, economists, political thinkers, and technological visionaries. These are AI analytical frameworks, not reports written or endorsed by the people who inspired them.

Each asset is analyzed separately through multiple frameworks and configurations, using specialized inputs and task instructions. Different perspectives examine different questions: valuation, business quality, technological disruption, macroeconomic conditions, political influence, financial risks, and more.

Cloud infrastructure allows these workflows to run at scale. That scale also comes with quality assurance at scale: up to 30% of report-generation attempts fail our QA checks. We rerun failed attempts until a clean report passes those checks. Users are presented only with reports that have passed QA.

This explains the volume. The value comes from what we do with the analysis.

A second layer synthesizes the individual reports into an asset-level consensus. This is where we recommend starting when researching a particular asset: it brings together the central thesis, supporting evidence, risks, and disagreements while preserving access to the underlying opinions.

We then compare assets through our proprietary iPulse AI Consensus Score, whose methodology is publicly explained. This helps users move from understanding one asset to comparing opportunities across the analyzed universe.

A further research and editorial layer examines leading candidates, checks current evidence, and develops focused Editorial Top Picks across broad-market and dedicated asset categories. Human editors review the evidence and approve each published edition. For example, explore our Best Long-Term Investments.

But the process does not end when a report is published. We preserve past forecasts so users with the relevant subscription can inspect what the system actually said and compare it with subsequent market outcomes. As more forecasts reach their target dates, the historical record becomes more useful for evaluating which approaches worked, which failed, and under what conditions.

We publish research on our website, arXiv, and Zenodo, alongside explanatory writing on Medium. We use the evidence to refine our data, frameworks, validation, and workflows, and document important findings in Lessons Learned.

The standard we ask users to judge us by is the reasoning, evidence, and historical record behind the research.

How does the iPulse AI Engine work?

The engine runs AI advisor configurations against a shared set of research inputs. The engine history explains the research workflow and what changed between versions.